European congress of cardiology 2021, results of the main studies, new clinical guidelines
Preserved study, empagliflozin, compared with placebo, reduced the risk of cardiovascular death and hospitalization due to chronic heart failure with a preserved left ventricular ejection fraction, regardless of the presence or absence of diabetes mellitus in the patient. The MASTER-DAPT study showed that the reduction in the duration of double antiplatelet therapy in patients with drug-coated stent transplantation is comparable in effectiveness with standard therapy. The ACST-2 study did not reveal any differences in the frequency of fatal or non-fatal stroke in patients with severe carotid stenosis, depending on the stenting or carotid endarterectomy. Replacing table salt with an alternative mixture in the SSaSS study confirmed the values of a low-salt diet in the prevention of cardiovascular diseases. The effectiveness of intensive control of arterial hypertension in elderly patients was demonstrated by the STEP study. The most significant results of the European Congress of Cardiology in 2021 were the adoption of four new versions of clinical practical recommendations, which reflected the results, including the above-mentioned studies. These are Recommendations for the prevention of cardiovascular diseases; Recommendations for valvular heart disease; Recommendations for the treatment of acute and chronic heart failure and Recommendations for pacing and cardiosynchronizing therapy